Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
A growing body of evidence suggests that infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) during pregnancy may affect maternal-fetal outcomes, with possible implications for the long-term development of exposed children.
Objective:
The PRegnancy OUtcomes and child Development Effects of SARS-CoV-2 infection STudy (PROUDEST) is a multicenter prospective study designed to understand the repercussions of COVID-19 to mother-child global health.
Methods:
The PROUDEST study comprises two prospective sequential substudies. The PREGNANT substudy will assess the effects of SARS-CoV-2 infection on pregnancy, childbirth and puerperium clinically and from a mechanistic standpoint to understand the inflammatory and immunological phenomena underlying COVID-19 in relation to pregnancy. Pregnant women aged 18 to 40 years with laboratory-proven exposure to SARS-CoV-2 (group A, n = 300) will be compared to control subjects with no laboratory evidence of in-pregnancy exposure to the virus (group B, n = 300). Subjects exposed to other infections during pregnancy will be excluded. The BORN substudy is a long-term follow-up study assessing the offspring of women who entered the prior substudy. It will describe the effects of SARS-CoV-2 exposure during pregnancy on children’s growth, neurodevelopment and metabolism from birth up to five years of age. It includes two comparison groups: group A (exposed, n = 300) comprises children born from SARS-CoV-2-exposed pregnancies, and group B (controls, n = 300) comprises children from nonexposed mothers.
Results:
Recruitment began in July 2020, and as of September 2020, 115 pregnant women infected with SARS-CoV-2 during pregnancy and 80 newborns had been included. Data
analysis is scheduled to start after all data have been collected.
Conclusions:
Upon completion of the study, we expect to have obtained comprehensive data to provide a better understanding of the effects of SARS-CoV-2 and its inflammatory and immunological processes on pregnancy, puerperium and infancy. Our findings will inform clinical decisions regarding the care of exposed mothers and children and support the development of evidence-based public health policies. Clinical Trial: The PROUDEST study was retrospectively registered on the Brazilian Register of Clinical Trials website (REBEC, https://ensaiosclinicos.gov.br/rg/RBR-65qxs2/, study ID RBR-65qxs2.
Citation
Please cite as:
Fernandes GM, Motta F, Sasaki LMP, Silva ÃPD, Miranda AM, Carvalho AOD, Gomides APG, Soares AADSM, Santos ADCMD Jr, Alves CDO, Gomes CM, Siracusa CCD, Araújo DAD Jr, Silva DLMD, Jesus JALD, Costa KN, Castro MECD, Kurisky PS, França PS, Tristão RM, Pereira YR, Castro LCGD, Zaconeta AM, Albuquerque CPD, Mota LMHD
Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection (PROUDEST Trial): Protocol for a Multicenter, Prospective Cohort Study